Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

27.40 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
This Red-Hot Growth Stock Has Soared 885% in Just 12 Months
Is it too late to buy shares of Viking Therapeutics? 
Via The Motley Fool
Why Viking Therapeutics Stock Is Heating Up Today
Positive analyst coverage is fueling another uptick in the biotech's stock today. 
Via The Motley Fool
2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87% Higher, According to Wall Street
Recent moves to the upside could be the beginning of a much larger bull run. 
Via The Motley Fool
3 Biotech Stocks Sitting on Huge-Upside Catalysts
The biotech boom is hot. According to Grand View, it could be worth $2.44 trillion. It's why we have an eye on these top biotech stocks. 
Via InvestorPlace
Viking Therapeutics Inc. (NASDAQ: VKTX) is a Stock Spotlight on 5/23
Via Investor Brand Network
The Important — And Overlooked — Caveat Behind Pfizer's Rival To Novo Nordisk In Diabetes
Pfizer stock surged on its diabetes news this week, but one analyst says there's a key piece missing from the story. 
Via Investor's Business Daily
Why Viking Therapeutics Stock Is Buckling Today
The biotech's shares can't escape the broader downward trend among its peer group today. 
Via The Motley Fool
What 17 Analyst Ratings Have To Say About Viking Therapeutics
Via Benzinga
Why Viking Therapeutics Stock Bolted Higher Today
The biotech's midstage NASH candidate passed another key hurdle. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss
Pfizer's diabetes drug led to faster weight loss than Novo Nordisk's Ozempic. 
Via Investor's Business Daily
Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug
The FDA's advisors voted resoundingly against accelerated approval for obeticholic acid. 
Via Investor's Business Daily
Hero or Zero? 3 High-Risk Biotech Stocks to Make You Rich … or Broke.
These biotech companies are swinging for the fences. They may hit homers, they may strike out. But you'll definitely want to watch them. 
Via InvestorPlace
7 Stocks That Wall Street Analysts Are Loving in May
Though not perfect, an analyst rating can indicate where institutional investor sentiment lies; here are seven stocks that analysts love. 
Via InvestorPlace
Why Viking Therapeutics Stock Wobbled Today
The biotech's shares dipped along with the broader markets in early-morning trading today. 
Via The Motley Fool
Why Viking Therapeutics Stock Briefly Popped Today
The biotech's shares rose briefly this morning following a sizable price target revision by an investing firm. 
Via The Motley Fool
Expert Ratings for Viking Therapeutics
Via Benzinga
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial
Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in  
Via Benzinga
Is Novo Nordisk Stock a Screaming Buy Right Now?
The drugmaker's shares have crushed the broader markets over the past two years. Can it keep up this blistering momentum? 
Via The Motley Fool
Why Top 1% Biotech Viking Therapeutics Is At The Brink Of A Record High
The company is working on a treatment for nonalcoholic steatohepatitis, or NASH. 
Via Investor's Business Daily
Why Viking Therapeutics Stock Is Trading Higher Tuesday
Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher Tuesday after the company announced positive top-line results from a Phase 
Via Benzinga
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
These three biotech stocks were on the volatile side today. 
Via The Motley Fool
Eli Lilly's Diabetes Newcomer, Mounjaro, Just Blew Sales Projections Out Of The Water
Mounjaro topped first-quarter sales expectations by more than $100 million. 
Via Investor's Business Daily
Earnings Preview For Viking Therapeutics
Via Benzinga
Earnings Scheduled For April 26, 2023
Companies Reporting Before The Bell • Teck Resources (NYSE:TECK) is expected to report quarterly earnings at $1.36 per share on revenue of $3.11 billion. 
Via Benzinga
3 Top Biotech Stocks Defying the Bear Market
All three companies have therapies with strong sales potential. 
Via The Motley Fool
Here are 2 Top Drug Makers Leading the Way in Weight Loss Drugs
The topic of weight loss drugs has been making recent headlines. The positive phase 1 clinical trial for Viking Therapeutics Inc. (NASDAQ: VKTX) GLP-1 treatme 
Via MarketBeat
Novo Nordisk Surges To Another Record As Obesity Drugs Drive Higher Outlook
Demand for Wegovy and Ozempic prompted Novo to raise its full-year outlook. 
Via Investor's Business Daily
Red-Hot Obesity-Drug Maker Novo Nordisk Soars To Record On A $725 Million Deal
Novo Nordisk is already a leader in obesity treatment with Saxenda and Wegovy. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback